What is Travere Therapeutics, Inc.'s SG&A?

Travere Therapeutics, Inc. (TVTX) reported SG&A of $80.25M in Q1 2026.

How has Travere Therapeutics, Inc.'s SG&A changed year-over-year?

Travere Therapeutics, Inc.'s SG&A increased by 32.8% year-over-year, from $60.41M to $80.25M.

What is the long-term trend for Travere Therapeutics, Inc.'s SG&A?

Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s SG&A has grown at a 26.6% compound annual growth rate (CAGR), from $126.28M to $324.78M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Travere Therapeutics, Inc. TVTX SG&A

SG&A at other companies

Vertex PharmaceuticalsVRTX

$493.7M+24.5%

LQD

Liquidia CorporationLQDA

$46.94M+56.1%

BridgeBio PharmaBBIO

$163.9M+54.1%

PTC TherapeuticsPTCT

$86.18M+6.5%

United TherapeuticsUTHR

$184.1M+8.2%

Arrowhead ResearchARWR

——

Segments

By segment

See full

Reportable Segment$80.25M+32.8%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.13B+72.3%

Enterprise value$5.07B+65.5%

P/S9.6×-1.3×

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s SG&A?: Travere Therapeutics, Inc. (TVTX) reported SG&A of $80.25M in Q1 2026.
How has Travere Therapeutics, Inc.'s SG&A changed year-over-year?: Travere Therapeutics, Inc.'s SG&A increased by 32.8% year-over-year, from $60.41M to $80.25M.
What is the long-term trend for Travere Therapeutics, Inc.'s SG&A?: Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s SG&A has grown at a 26.6% compound annual growth rate (CAGR), from $126.28M to $324.78M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.